查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1936385

美国子痫前症检测市场：市场洞察、竞争格局与预测（2033 年）

U.S. Preeclampsia Laboratory Testing Market Insights, Competitive Landscape, and Market Forecast - 2033
出版日期: | 出版商: Fairfield Market Research | 英文 104 Pages | 商品交期: 2-5个工作天内

价格
简介目录

随着医疗保健机构日益重视子痫前症（一种影响孕妇的严重高血压疾病）的早期诊断和管理，美国子痫前症检测市场正经历显着增长。及时检测至关重要，因为如果未能及时发现，该疾病可能导致严重的母婴併发症。鑑于公众意识的提高、技术的进步以及高风险怀孕的增加，预计到 2026 年，美国子痫前症检测市场规模将达到 11 亿美元，到 2033 年将增长至 18 亿美元，复合年增长率 (CAGR) 为 6.70%。

市场洞察

近年来，子痫前症检测技术取得了显着进步。现代诊断方法包括尿液和血液检测，能够检测蛋白尿、肾臟和肝臟功能异常以及与子痫前症相关的特定生物标记。 这些检测不仅有助于疾病的早期发现，也能帮助医护人员监测病情严重程度。

免疫测定、高通量筛选和多重检测等技术进步提高了子痫前症诊断的准确性和速度。结合即时检测解决方案的引入，这些创新正在帮助临床医生及时干预，降低母婴风险。

此外，子痫前症发病率的上升，尤其是在患有高血压、糖尿病和肥胖等潜在疾病的女性中，凸显了可靠诊断解决方案的必要性。将检测纳入标准产前护理方案对于有效管理高风险怀孕至关重要。

市场驱动因素

美国子痫前症检测市场的成长受到多种因素的推动。其中一个关键驱动因素是医护人员和病患对孕产妇健康併发症的认识不断提高。 目前的产前保健计画强调早期筛检和定期监测，从而提高了检测的普及率。

技术创新也是关键驱动因素。先进的诊断平台，例如酶联免疫吸附试验 (ELISA)、生物标记检测和快速即时检测设备，提高了子痫前症检测的灵敏度和特异性。这使得早期发现更加可行和可靠，从而能够进行主动管理。

政府的各项措施和以妇幼健康为重点的公共卫生计画也在推动市场成长。产前诊断检测的资金投入、保险覆盖范围的扩大以及宣传活动的开展，促使医院和实验室采用先进的子痫前症检测方案。

由于孕妇年龄增长、肥胖以及生活方式相关疾病等原因，高风险妊娠的增加进一步推动了对子痫前症诊断检测的需求。不断增长的患者群体推动了对频繁监测和先进检测的需求，从而支持了市场的持续扩张。

商机

美国子痫前症检测市场为成熟和新兴的诊断公司提供了充足的机会。生物标记检测、多重检测和快速诊断的创新有望推动医院、诊所和诊断中心对这些检测方法的采用。

诊断公司与医疗保健提供者之间的合作将推动市场渗透。对发现新的生物标记和建构更精准的检测平台进行研发投资，可望带来竞争优势。此外，整合远距医疗报告和远端监测等数位化解决方案可以简化检测流程并改善患者护理。

区域分析

在北美妊娠高血压检测市场，美国凭藉其先进的医疗基础设施、较高的公众意识和尖端诊断技术的广泛应用，占领先地位。加州、德州、纽约州和佛罗里达州是推动市场成长的主要地区，这些地区拥有大量三级医院和妇幼保健中心。

虽然城市地区持续加快检测普及，但得益于政府资助的产前保健项目和移动诊断服务的扩展，郊区和农村地区也在逐步迎头赶上。预计这些措施将在预测期内改善市场覆盖率和患者就医便利性，并减少医疗保健服务的区域差异。

主要参与者

全球子痫前症检测市场竞争激烈，主要参与者专注于产品创新、策略合作和研究计画。代表性市场参与者包括：

  • DiabetOmics
  • DRG Instruments GmbH
  • F.罗氏有限公司
  • GestVision公司
  • Lifeassay Diagnostics（私人）有限公司
  • Metabolomic Diagnostics
  • Perkin Elmer公司
  • Progenity公司
  • Quidel公司
  • 西门子医疗
  • 赛默飞世尔科技公司

这些公司利用先进的诊断技术和生物标记研究，保持强大的市场地位，并满足产前护理提供者和患者日益增长的需求。

市场区隔

为了全面了解全球子痫前症检测市场的发展趋势，可将其细分为以下几个部分：

依检测类型：

  • 尿液检测
  • 血液检测

依子痫前症类型：

  • 轻度子痫前症
  • 重度子痫前症

依最终用户：

  • 医院和诊所
  • 诊断中心
  • 其他

依地区：

  • 美国

目录

第一章：摘要整理摘要

第二章 市场概览

  • 市场定义与细分
  • 市场动态
    • 驱动因素
    • 限制因素
    • 市场机遇
  • 价值链分析
  • 新冠疫情影响分析
  • 波特五力分析
  • 俄乌衝突的影响
  • PESTLE分析
  • 监理分析
  • 价格趋势分析
    • 当前价格及未来预测（2025-2033年）
    • 价格影响因素

第三章 全球子痫前症检测市场预测（2020-2033）

  • 全球子痫前症检测市场依检测类型划分的全球子痫前程检测市场预测（收入，单位：十亿美元），2020-2033 年
    • 尿液检测
    • 血液检测
  • 依子痫前症类型划分的全球子痫前症检测市场预测（收入，单位：十亿美元），2020-2033 年
    • 轻度子痫前症
    • 重度子痫前症
  • 依最终用户划分的全球子痫前症检测市场预测（价值，单位：十亿美元），2020-2033 年
    • 医院和诊所
    • 诊断中心
    • 其他
  • 依地区划分的全球子痫前期检测市场预测（价值，单位：十亿美元），2020-2033 年
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东东非和非洲

第四章：北美子痫前症检测市场展望（2020-2033）

第五章：欧洲子痫前症检测市场展望（2020-2033）

第六章：亚太地区子痫前症检测市场展望（2020-2033）

第七章：拉丁美洲子痫前症检测市场展望（2020-2033）

第八章：中东与非洲子痫前症检测市场展望（2020-2033）

第九章：竞争格局

  • 公司与细分市场热力图
  • 公司市占率分析2025
  • 竞争格局概览
  • 公司简介
    • DiabetOmics
    • DRG Instruments GmbH
    • F. Hoffmann-La Roche Ltd.
    • GestVision, Inc.
    • Lifeassay Diagnostics (Pty) Ltd.
    • Metabolomic Diagnostics
    • Perkin Elmer, Inc.
    • Progenity, Inc.
    • Quidel Corporation
    • Siemens Healthineers

第十章附录

简介目录

The U.S. Preeclampsia Laboratory Testing Market is experiencing notable growth as healthcare providers increasingly focus on early diagnosis and management of preeclampsia-a serious hypertensive disorder affecting pregnant women. The condition, if left undetected, can result in severe complications for both mother and child, making timely laboratory testing essential. In response to rising awareness, technological advancements, and the growing prevalence of high-risk pregnancies, the U.S. market for preeclampsia laboratory testing is projected to reach USD 1.1 billion by 2026 and is expected to expand to USD 1.8 billion by 2033, representing a compound annual growth rate (CAGR) of 6.70%.

Market Insights

Laboratory testing for preeclampsia has progressed significantly over the years. Modern diagnostics include both urine and blood-based tests, allowing for the detection of proteinuria, kidney and liver function abnormalities, and specific biomarkers associated with preeclampsia. These tests not only help identify the condition early but also assist healthcare professionals in monitoring its severity.

Technological advancements such as immunoassays, high-throughput screening, and multiplex testing panels have enhanced the accuracy and speed of preeclampsia diagnosis. Combined with the adoption of point-of-care testing solutions, these innovations are helping clinicians provide timely interventions, reducing maternal and neonatal risks.

Furthermore, increasing incidences of preeclampsia, particularly among women with pre-existing conditions like hypertension, diabetes, or obesity, underscore the growing need for reliable diagnostic solutions. The integration of laboratory testing into standard prenatal care protocols has become critical in managing high-risk pregnancies effectively.

Market Drivers

Several factors are fueling the growth of the U.S. preeclampsia laboratory testing market. One of the primary drivers is growing awareness of maternal health complications among healthcare professionals and patients alike. Prenatal care programs now emphasize early screening and regular monitoring, prompting higher adoption of laboratory tests.

Technological innovation is another key driver. Advanced diagnostic platforms, including enzyme-linked immunosorbent assays (ELISA), biomarker panels, and rapid point-of-care devices, have improved both sensitivity and specificity in detecting preeclampsia. This has made early detection more feasible and reliable, enabling proactive management.

Government initiatives and public health programs focusing on maternal and child health are also supporting market growth. Funding for prenatal diagnostic testing, insurance coverage, and awareness campaigns have collectively encouraged hospitals and diagnostic laboratories to incorporate advanced preeclampsia testing solutions.

The rising number of high-risk pregnancies, influenced by delayed childbirth, obesity, and lifestyle-related health conditions, has further amplified demand for preeclampsia diagnostic tests. As the patient pool grows, the need for frequent monitoring and advanced testing continues to rise, supporting sustained market expansion.

Business Opportunities

The U.S. preeclampsia laboratory testing market presents ample opportunities for both established and emerging diagnostic companies. Innovations in biomarker detection, multiplex assays, and rapid diagnostics are expected to drive adoption across hospitals, clinics, and diagnostic centers.

Collaborations between diagnostic companies and healthcare providers can enhance market penetration. Investment in research and development to discover novel biomarkers and create more precise testing platforms will likely provide a competitive edge. Moreover, integrating digital solutions, such as telemedicine-enabled reporting and remote monitoring, can streamline testing processes and improve patient care.

Regional Analysis

The United States dominates the North American preeclampsia laboratory testing market due to its advanced healthcare infrastructure, high awareness levels, and availability of cutting-edge diagnostic technologies. Key regions contributing to market growth include California, Texas, New York, and Florida, which host a concentration of tertiary care hospitals and maternal health centers.

Urban centers continue to adopt laboratory testing at a faster pace, while suburban and rural areas are gradually catching up thanks to government-funded prenatal programs and mobile diagnostic initiatives. These efforts are expected to improve market reach and patient access over the forecast period, reducing regional disparities in healthcare services.

Key Players

The U.S. preeclampsia laboratory testing market is highly competitive, with leading companies focusing on product innovation, strategic partnerships, and research initiatives. Prominent market participants include:

  • DiabetOmics
  • DRG Instruments GmbH
  • F. Hoffmann-La Roche Ltd.
  • GestVision, Inc.
  • Lifeassay Diagnostics (Pty) Ltd.
  • Metabolomic Diagnostics
  • Perkin Elmer, Inc.
  • Progenity, Inc.
  • Quidel Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

These companies are leveraging advanced diagnostic technologies and biomarker research to maintain a strong presence in the market while addressing the growing needs of prenatal healthcare providers and patients.

Market Segmentation

The U.S. preeclampsia laboratory testing market can be segmented to provide a comprehensive understanding of its dynamics:

By Test Type:

  • Urine Tests
  • Blood Tests

By Preeclampsia Type:

  • Mild Preeclampsia
  • Severe Preeclampsia

By End User:

  • Hospitals and Clinics
  • Diagnostic Centres
  • Others

By Region:

  • U.S.

Table of Contents

1. Executive Summary

  • 1.1. U.S. Preeclampsia Laboratory Testing Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2026
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Porter's Fiver Forces Analysis
  • 2.6. Impact of Russia-Ukraine Conflict
  • 2.7. PESTLE Analysis
  • 2.8. Regulatory Analysis
  • 2.9. Price Trend Analysis
    • 2.9.1. Current Prices and Future Projections, 2025-2033
    • 2.9.2. Price Impact Factors

3. Global U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 3.1. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 3.1.1. Urine Tests
    • 3.1.2. Blood Tests
  • 3.2. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 3.2.1. Mild Preeclampsia
    • 3.2.2. Severe Preeclampsia
  • 3.3. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 3.3.1. Hospitals and Clinics
    • 3.3.2. Diagnostic Centres
    • 3.3.3. Others
  • 3.4. Global U.S. Preeclampsia Laboratory Testing Market Outlook, by Region, Value (US$ Bn), 2020-2033
    • 3.4.1. North America
    • 3.4.2. Europe
    • 3.4.3. Asia Pacific
    • 3.4.4. Latin America
    • 3.4.5. Middle East & Africa

4. North America U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 4.1. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 4.1.1. Urine Tests
    • 4.1.2. Blood Tests
  • 4.2. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 4.2.1. Mild Preeclampsia
    • 4.2.2. Severe Preeclampsia
  • 4.3. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 4.3.1. Hospitals and Clinics
    • 4.3.2. Diagnostic Centres
    • 4.3.3. Others
  • 4.4. North America U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 4.4.1. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.2. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 4.4.3. U.S. U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 4.4.4. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 4.4.5. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 4.4.6. Canada U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 4.5. BPS Analysis/Market Attractiveness Analysis

5. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 5.1. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 5.1.1. Urine Tests
    • 5.1.2. Blood Tests
  • 5.2. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 5.2.1. Mild Preeclampsia
    • 5.2.2. Severe Preeclampsia
  • 5.3. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 5.3.1. Hospitals and Clinics
    • 5.3.2. Diagnostic Centres
    • 5.3.3. Others
  • 5.4. Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 5.4.1. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.2. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.3. Germany U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.4. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.5. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.6. Italy U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.7. France U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.8. France U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.9. France U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.10. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.11. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.12. U.K. U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.13. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.14. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.15. Spain U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.16. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.17. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.18. Russia U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 5.4.19. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 5.4.20. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 5.4.21. Rest of Europe U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 5.5. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 6.1. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 6.1.1. Urine Tests
    • 6.1.2. Blood Tests
  • 6.2. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 6.2.1. Mild Preeclampsia
    • 6.2.2. Severe Preeclampsia
  • 6.3. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 6.3.1. Hospitals and Clinics
    • 6.3.2. Diagnostic Centres
    • 6.3.3. Others
  • 6.4. Asia Pacific U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 6.4.1. China U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.2. China U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.3. China U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.4. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.5. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.6. Japan U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.7. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.8. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.9. South Korea U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.10. India U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.11. India U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.12. India U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.13. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.14. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.15. Southeast Asia U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 6.4.16. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 6.4.17. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 6.4.18. Rest of SAO U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 6.5. BPS Analysis/Market Attractiveness Analysis

7. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 7.1. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 7.1.1. Urine Tests
    • 7.1.2. Blood Tests
  • 7.2. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 7.2.1. Mild Preeclampsia
    • 7.2.2. Severe Preeclampsia
  • 7.3. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 7.3.1. Hospitals and Clinics
    • 7.3.2. Diagnostic Centres
    • 7.3.3. Others
  • 7.4. Latin America U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 7.4.1. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.2. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.3. Brazil U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.4. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.5. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.6. Mexico U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.7. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.8. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.9. Argentina U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 7.4.10. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 7.4.11. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 7.4.12. Rest of LATAM U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 7.5. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, 2020 - 2033

  • 8.1. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, Value (US$ Bn), 2020-2033
    • 8.1.1. Urine Tests
    • 8.1.2. Blood Tests
  • 8.2. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, Value (US$ Bn), 2020-2033
    • 8.2.1. Mild Preeclampsia
    • 8.2.2. Severe Preeclampsia
  • 8.3. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, Value (US$ Bn), 2020-2033
    • 8.3.1. Hospitals and Clinics
    • 8.3.2. Diagnostic Centres
    • 8.3.3. Others
  • 8.4. Middle East & Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Country, Value (US$ Bn), 2020-2033
    • 8.4.1. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.2. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.3. GCC U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.4. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.5. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.6. South Africa U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.7. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.8. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.9. Egypt U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.10. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.11. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.12. Nigeria U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
    • 8.4.13. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by Test Type, 2020-2033
    • 8.4.14. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by Preeclampsia Type, 2020-2033
    • 8.4.15. Rest of Middle East U.S. Preeclampsia Laboratory Testing Market Outlook, by End User, 2020-2033
  • 8.5. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Company Vs Segment Heatmap
  • 9.2. Company Market Share Analysis, 2025
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. DiabetOmics
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Developments
    • 9.4.2. DRG Instruments GmbH
    • 9.4.3. F. Hoffmann-La Roche Ltd.
    • 9.4.4. GestVision, Inc.
    • 9.4.5. Lifeassay Diagnostics (Pty) Ltd.
    • 9.4.6. Metabolomic Diagnostics
    • 9.4.7. Perkin Elmer, Inc.
    • 9.4.8. Progenity, Inc.
    • 9.4.9. Quidel Corporation
    • 9.4.10. Siemens Healthineers

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations